|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-11-5
|
|
pubmed:abstractText |
The number of agents that are active in patients with metastatic melanoma is limited and cure is not a realistic objective for treatment at this stage. The aim of the study was to evaluate the efficacy and safety of new combination regimen cosisting of docetaxel and dacarbazine (DTIC), as first-line chemotherapy, in patients with advanced melanoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
333-7
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12417787-Adult,
pubmed-meshheading:12417787-Aged,
pubmed-meshheading:12417787-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12417787-Dacarbazine,
pubmed-meshheading:12417787-Female,
pubmed-meshheading:12417787-Humans,
pubmed-meshheading:12417787-Male,
pubmed-meshheading:12417787-Melanoma,
pubmed-meshheading:12417787-Middle Aged,
pubmed-meshheading:12417787-Neoplasm Metastasis,
pubmed-meshheading:12417787-Paclitaxel,
pubmed-meshheading:12417787-Remission Induction,
pubmed-meshheading:12417787-Skin Neoplasms,
pubmed-meshheading:12417787-Survival Analysis,
pubmed-meshheading:12417787-Taxoids
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
|
|
pubmed:affiliation |
Metropolitan Hospital, Athens, Greece. hesmo@compulink.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
